Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 6/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | TYK2 | P29597 | 7/20 | 0.51 |
| ▸ | JAK1 | P23458 | 6/20 | 0.51 |
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | ULK1 | O75385 | 2/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690590 | 0.87 | MAPK10 (0.65) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL29777593 | 0.87 | MAPK10 (0.65) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL12887553 | 0.86 | MAPK10 (0.52) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL12887142 | 0.85 | MAPK10 (0.49) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL14068363 | 0.85 | MAPK10 (0.49) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL12413721 | 0.85 | TYK2 (0.56) | MAPK10TYK2JAK1JAK2MAPK9 | |
| SCHEMBL691337 | 0.85 | MAPK10 (0.51) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL13060634 | 0.85 | MAPK10 (0.51) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL18559472 | 0.84 | MAPK10 (0.48) | MAPK10MAPK8TYK2JAK1JAK2 | |
| SCHEMBL30692349 | 0.84 | MAPK10 (0.64) | MAPK10MAPK8MAPK9PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| EP-2303861-A1 | PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| EP-2249650-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GlaxoSmithKline LLC (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009105498-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105498-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | PTK2, JAK2, SRC | MAPK10 386/4885MAPK8 779/4885TYK2 657/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | MAPK10 301/4885MAPK8 376/4885TYK2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.